WO2003048108A3 - Compounds for treatment of inflammation, diabetes and related disorders - Google Patents

Compounds for treatment of inflammation, diabetes and related disorders Download PDF

Info

Publication number
WO2003048108A3
WO2003048108A3 PCT/US2002/038150 US0238150W WO03048108A3 WO 2003048108 A3 WO2003048108 A3 WO 2003048108A3 US 0238150 W US0238150 W US 0238150W WO 03048108 A3 WO03048108 A3 WO 03048108A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inflammation
treatment
diabetes
diabetes mellitus
Prior art date
Application number
PCT/US2002/038150
Other languages
French (fr)
Other versions
WO2003048108A2 (en
Inventor
Partha Neogi
Debendranath Dey
Ta-Kai Li
Joseph Fuller
Liang Chen
Original Assignee
Calyx Therapeutics Inc
Partha Neogi
Debendranath Dey
Ta-Kai Li
Joseph Fuller
Liang Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02804467A priority Critical patent/EP1448515A2/en
Application filed by Calyx Therapeutics Inc, Partha Neogi, Debendranath Dey, Ta-Kai Li, Joseph Fuller, Liang Chen filed Critical Calyx Therapeutics Inc
Priority to KR1020047008107A priority patent/KR100941197B1/en
Priority to MXPA04005168A priority patent/MXPA04005168A/en
Priority to CA2468302A priority patent/CA2468302C/en
Priority to AU2002357032A priority patent/AU2002357032B2/en
Priority to CN028271009A priority patent/CN1615295B/en
Priority to NZ533645A priority patent/NZ533645A/en
Priority to US10/430,677 priority patent/US7323496B2/en
Publication of WO2003048108A2 publication Critical patent/WO2003048108A2/en
Publication of WO2003048108A3 publication Critical patent/WO2003048108A3/en
Priority to US12/004,064 priority patent/US20080103302A1/en
Priority to US12/004,075 priority patent/US20080188654A1/en
Priority to US12/004,039 priority patent/US20080108825A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction, in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunological diseases and cancer.
PCT/US2002/038150 1999-11-08 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders WO2003048108A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN028271009A CN1615295B (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
KR1020047008107A KR100941197B1 (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
MXPA04005168A MXPA04005168A (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders.
CA2468302A CA2468302C (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
AU2002357032A AU2002357032B2 (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
EP02804467A EP1448515A2 (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
NZ533645A NZ533645A (en) 2001-11-29 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders
US10/430,677 US7323496B2 (en) 1999-11-08 2003-05-07 Compounds for treatment of inflammation, diabetes and related disorders
US12/004,075 US20080188654A1 (en) 2001-11-29 2007-12-20 Compounds for treatment of inflammation, diabetes and related disorders
US12/004,064 US20080103302A1 (en) 2000-02-04 2007-12-20 Compounds for treatment of inflammation, diabetes and related disorders
US12/004,039 US20080108825A1 (en) 1999-11-08 2007-12-20 Compounds for treatment of inflammation, diabetes and related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33481801P 2001-11-29 2001-11-29
US60/334,818 2001-11-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/777,551 Continuation-In-Part US20020002200A1 (en) 1999-11-08 2001-02-05 Novel diphenylethylene compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10430667 Continuation-In-Part 2003-05-05
US10/430,677 Continuation-In-Part US7323496B2 (en) 1999-11-08 2003-05-07 Compounds for treatment of inflammation, diabetes and related disorders

Publications (2)

Publication Number Publication Date
WO2003048108A2 WO2003048108A2 (en) 2003-06-12
WO2003048108A3 true WO2003048108A3 (en) 2003-10-16

Family

ID=23308958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038150 WO2003048108A2 (en) 1999-11-08 2002-11-27 Compounds for treatment of inflammation, diabetes and related disorders

Country Status (9)

Country Link
EP (1) EP1448515A2 (en)
KR (1) KR100941197B1 (en)
CN (1) CN1615295B (en)
AU (2) AU2002357032B2 (en)
CA (1) CA2468302C (en)
MX (1) MXPA04005168A (en)
NZ (2) NZ533645A (en)
SG (1) SG165988A1 (en)
WO (1) WO2003048108A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU2003260033A1 (en) * 2002-08-29 2004-03-19 Schering Aktiengesellschaft Methods of treating acute respiratory distress syndrome
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US8034921B2 (en) 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
US20130197043A1 (en) 2010-08-31 2013-08-01 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
ES2526660T3 (en) * 2010-10-07 2015-01-14 Zadec Aps Enidia glycoside of antidiabetic phenylpyruvic acid
KR20120048250A (en) * 2010-11-05 2012-05-15 숙명여자대학교산학협력단 Anti-inflammatory composition containing thiourea compound or pharmaceutically acceptable salts thereof as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254549A1 (en) * 1973-12-12 1975-07-11 Takeda Chemical Industries Ltd 3-(Substd. phenyl)-2-chloropropionic acid derivs - hypolipidaemics and hypoglycaemics
WO2001034094A2 (en) * 1999-11-08 2001-05-17 Calyx Therapeutics, Inc. Novel compounds to treat diabetes and associated conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006472B1 (en) * 1987-05-07 1997-04-28 오노 화아마슈티칼 캄파니 리미팃드 Novel cinnamoylamide derivatives
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE19527305A1 (en) * 1995-07-26 1997-01-30 Hoechst Ag Substituted cinnamic acid guanidides, process for their preparation, their use as a medicament or diagnostic agent and medicament containing them
UA74781C2 (en) * 1999-04-02 2006-02-15 Abbott Lab Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion
DE19941764A1 (en) * 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituted acylguanidines, processes for their preparation, their use as medicines or diagnostics and medicines containing them
CA2383794A1 (en) * 1999-09-07 2001-03-15 Conjuchem Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DE10024319A1 (en) * 2000-05-17 2001-11-22 Merck Patent Gmbh New bis-acylguanidine compounds are subtype-1 cellular sodium ion-proton antiporter inhibitors useful e.g. for treating arrhythmia, angina pectoris, infarction and insulin-independent diabetes mellitus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254549A1 (en) * 1973-12-12 1975-07-11 Takeda Chemical Industries Ltd 3-(Substd. phenyl)-2-chloropropionic acid derivs - hypolipidaemics and hypoglycaemics
WO2001034094A2 (en) * 1999-11-08 2001-05-17 Calyx Therapeutics, Inc. Novel compounds to treat diabetes and associated conditions

Also Published As

Publication number Publication date
WO2003048108A2 (en) 2003-06-12
CA2468302A1 (en) 2003-06-12
KR20040091609A (en) 2004-10-28
AU2002357032A1 (en) 2003-06-17
CN1615295A (en) 2005-05-11
CN1615295B (en) 2010-11-03
NZ533645A (en) 2008-04-30
AU2009201342A1 (en) 2009-04-30
CA2468302C (en) 2012-08-14
SG165988A1 (en) 2010-11-29
KR100941197B1 (en) 2010-02-10
AU2002357032B2 (en) 2009-01-08
EP1448515A2 (en) 2004-08-25
MXPA04005168A (en) 2005-02-17
NZ563604A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2004101752A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
CY1112845T1 (en) PRODUCTS OF 1-DEOXY-LACTONOGIRIMYKIN AND THEIR USE IN THE TREATMENT OF ATHLETIC LYSOSOMIC DISEASES THROUGH ENHANCEMENT OF LYSOSIM A
WO2005033102A3 (en) Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
IL166571A0 (en) Medical treatment system by substituting native biological regulatory function: cardiac pacing system blood pressure regulating system and cardiac disease treatment system based on the medical system
WO2005052115A3 (en) Use of parasitic biological agents for diseases prevention and control
AU2003269820A8 (en) Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
MXPA05003781A (en) Novel heterocyclic analogs of diphenylethylene compounds.
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
PL1639013T3 (en) Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
WO2004028341A3 (en) Susceptibility gene for human stroke; methods of treatment
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003304410A1 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
WO2003048108A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2006124686A3 (en) Modulation of stat 6 expression for the treatment of airway hyperresponsiveness
WO2002062327A3 (en) Method of treating neurological disorders using acetone derivatives
AU2003272945A1 (en) Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction
WO2001072328A3 (en) Methods of treating diseases with activated protein c
WO2003099105A3 (en) Diagnosis and treatment of human dormancy syndrome
EP1632241A4 (en) Preventive and/or remedy for diseases accompanied by tissue destruction
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
AU2003223780A1 (en) Treatment for pompe disease
NO20043483L (en) Use of melagatran for the manufacture of a drug for the treatment of type 1 diabetes mellitus
WO2005063757A3 (en) Novel crystalline forms of temozolomide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10430677

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2468302

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002804467

Country of ref document: EP

Ref document number: 1162/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005168

Country of ref document: MX

Ref document number: 1020047008107

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002357032

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 533645

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20028271009

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002804467

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10430677

Country of ref document: US